ArticleInternational journal of general medicine2025
Gustave Roussy Immune Score (GRImScore) as a Novel Prognostic Index for Stage III Gastric Cancer Patients: A Real-World Retrospective Study.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gustave Roussy Immune (GRIm) score as a novel prognostic biomarker for gastrointestinal cancers: a meta-analysis of sixteen studies.World journal of surgical oncology · 2026Pooled it
- GRIm Score Predicts Curative Conversion Surgery in Unresectable Gastric Cancer.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate whether Gustave Roussy immune score (GRImScore) serves as a novel prognostic index for predicting survival in patients with advanced gastric cancer. Methods: GRImScore was based on three objective markers: (1) albumin level (<3.5 g/L = 1 point, ≥3.5 g/L = 0 point); (2) lactate dehydrogenase level (≥250 U/L = 1 point, <250 U/L = 0 point); (3) neutrophil to lymphocyte ratio (NLR) (≥2.70 = 1 point, <2.70 = 0 point). According to GRImScore, these patients were divided into low GRImScore group (0 points) and high GRImScore group (1, 2, or 3 points). Kaplan-Meier method was applied to draw survival curves for disease free survival (DFS) and overall survival (OS), and differences among these groups were analyzed using Log rank tests. Univariate and multivariate Cox proportional hazards models were used to analyze the relationship between the enrolled parameters and OS. Nomograms were developed based on the results of multivariate Cox regression analysis using the consistency index (C-index) and decision curve analyses (DCA) for internal validation. Results: Based on GRImScore, 134 patients were in low GRImScore group and 61 were in high GRImScore group. The median DFS and OS in low GRImScore group were significantly longer than that in high GRImScore group (DFS: 40.52 months vs 22.83 months, χ Conclusion: GRImScore, a novel prognostic index, is a prognostic indicator for patients with advanced gastric cancer. Nomograms based on the GRImScore showed good predictive ability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.